NxStage Medical, Inc. (NASDAQ:NXTM) SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $23.14, for a total value of $80,990.00. Following the completion of the transaction, the senior vice president now directly owns 17,270 shares of the company’s stock, valued at approximately $399,627.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
NxStage Medical, Inc. (NASDAQ:NXTM) traded down 0.30% during midday trading on Friday, hitting $23.42. The stock had a trading volume of 799,473 shares. The firm’s market cap is $1.54 billion. NxStage Medical, Inc. has a 12-month low of $18.79 and a 12-month high of $30.80. The stock has a 50-day moving average price of $23.88 and a 200 day moving average price of $26.21.
NxStage Medical (NASDAQ:NXTM) last released its earnings results on Tuesday, May 9th. The medical device company reported ($0.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $96.83 million during the quarter, compared to analysts’ expectations of $95.31 million. NxStage Medical had a negative net margin of 1.25% and a negative return on equity of 2.31%. NxStage Medical’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.02) EPS. On average, equities analysts anticipate that NxStage Medical, Inc. will post ($0.03) earnings per share for the current fiscal year.
WARNING: “NxStage Medical, Inc. (NXTM) SVP Sells $80,990.00 in Stock” was posted by WKRB News and is the property of of WKRB News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.wkrb13.com/markets/2229035/nxstage-medical-inc-nxtm-svp-sells-80990-00-in-stock.html.
NXTM has been the subject of a number of analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of NxStage Medical in a report on Wednesday, March 22nd. Northland Securities reaffirmed a “buy” rating and issued a $35.00 price target on shares of NxStage Medical in a report on Monday, April 3rd. Canaccord Genuity reiterated a “buy” rating and set a $32.00 price objective on shares of NxStage Medical in a research note on Monday, May 8th. Finally, BTIG Research reiterated a “buy” rating and set a $27.00 price objective on shares of NxStage Medical in a research note on Wednesday, May 10th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. NxStage Medical presently has a consensus rating of “Buy” and an average price target of $30.20.
A number of hedge funds have recently added to or reduced their stakes in NXTM. BlackRock Inc. boosted its stake in NxStage Medical by 38,360.4% in the first quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after buying an additional 4,401,851 shares during the last quarter. Eagle Asset Management Inc. purchased a new stake in NxStage Medical during the first quarter valued at approximately $54,558,000. Perceptive Advisors LLC purchased a new stake in NxStage Medical during the fourth quarter valued at approximately $50,533,000. Loomis Sayles & Co. L P boosted its stake in NxStage Medical by 365.9% in the first quarter. Loomis Sayles & Co. L P now owns 708,946 shares of the medical device company’s stock valued at $19,021,000 after buying an additional 556,780 shares during the last quarter. Finally, Henderson Group PLC purchased a new stake in NxStage Medical during the first quarter valued at approximately $12,707,000. 94.89% of the stock is owned by hedge funds and other institutional investors.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229035/nxstage-medical-inc-nxtm-svp-sells-80990-00-in-stock.html
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.